Pioneering biotherapeutic delivery for the prevention and treatment of chronic lung disease

First-in-Class Inhaled Biotherapeutics

We are a team of scientists, clinicians, and engineers on a mission to disrupt the standard of care for chronic and infectious lung disease. Our proprietary resMIT platform delivers safe, targeted bacteria directly to the lungs to address fibroblast dysfunction in Idiopathic Pulmonary Fibrosis (IPF) and neutrophilic inflammation indications (NCFBE, COPD).

Join us in revolutionizing the standard of care
for chronic respiratory diseases